[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652029":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":72,"collaborators":31,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":31,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":31,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":31,"overallStatus":95,"whyStopped":31,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"NNC0721-8060","EXPERIMENTAL","Participants will receive subcutaneous injection of NNC0721-8060.",[13],"Drug: NNC0721-8060",{"label":15,"type":16,"description":17,"interventionNames":18},"Semaglutide","ACTIVE_COMPARATOR","Participants will receive subcutaneous injection of semaglutide.",[19],"Drug: Semaglutide",{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo","PLACEBO_COMPARATOR","Participants will receive subcutaneous injection of placebo.",[25],"Drug: Placebo",[27,32,35],{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","NNC0721-8060 will be administered subcutaneously.",[9],null,{"type":28,"name":15,"description":33,"armGroupLabels":34,"otherNames":31},"Semaglutide will be administered subcutaneously.",[15],{"type":28,"name":21,"description":36,"armGroupLabels":37,"otherNames":31},"Placebo will be administered subcutaneously.",[21],[39],{"name":40,"affiliation":5,"role":41},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":31,"email":47},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[49,62],{"facility":50,"status":31,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":31},"ICON Early Phase Services, LLC","Lenexa","Kansas","66219","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-94.73357,38.95362,{"lat":60,"lon":59},{"facility":63,"status":31,"city":64,"state":65,"zip":66,"country":54,"countryCode":55,"cosmosGeoPoint":67,"geoPoint":71,"contacts":31},"ICON","San Antonio","Texas","78209",{"type":57,"coordinates":68},[69,70],-98.49363,29.42412,{"lat":70,"lon":69},{"type":73,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100652029","phase-1-a-first-in-human-research-study-on-how-nnc0721-8060-works-in-people-living-with-overweight-or-obesity-100652029",false,"NCT07767175","A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity","A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18-55 years (both inclusive) at the time of signing informed consent.\n* Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg\u002Fm\\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.\n* Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous randomisation in this study.\n* History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.\n* Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.\n* Current participation (signed informed consent) in any other interventional clinical study.\n* Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.\n* Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.\n* Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \\[mmol\u002Fmol\\]) at screening.",true,"ALL","18 Years","55 Years",{"count":86,"type":87},142,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.",[93,94],"Overweight","Obesity","NOT_YET_RECRUITING","2026-08-11",{"date":98,"type":99},"2026-08-17","ACTUAL",{"date":101,"type":87},"2026-08-12",{"date":103,"type":87},"2027-09-23",{"name":5,"class":6},2]